Podcasts about anatomic pathology

In this episode, we'll be talking about a new dental approach to an old problem, and that's Oral Human papillomavirus, commonly referred to as HPV. Why is this virus so dangerous and how can we as dental professionals help save lives by screening for this insidious virus? To answer these questions and more, is our guest, Dr Mohammad Kamal. Dr Kamal completed his Pathology training at Harbor UCLA Medical Center in California, serving as a chief resident. He completed subspecialty fellowship training in Gastrointestinal and Liver Pathology at UCLA and he is board certified in Anatomic Pathology. Dr. Kamal served as Medical Director of LabCorp's Dianon Laboratory and as Chief Medical Officer for PLUS Diagnostics. Thanks to our episode sponsors: NSK America - https://www.nskdental.com/ Ivoclar - https://www.ivoclarusa.com/finder/makeitemax/index.php

In this SSO Education Series episode of SurgOnc Today®, Dr. Seth Concors, an Assistant Professor of Surgical Oncology at Emory University interviews Dr. Aatur Singhi, an Associate Professor in the Divisions of Anatomic Pathology and Molecular Genomic Pathology, Director and Coordinator of Anatomic Pathology Research and Director of the UPMC Developmental Laboratory, who reviews the fundamentals of appendiceal pathology – reviewing recent changes relevant for clinical management.

There's no question there's been an ongoing buzz and growing interest among dental professionals in, what is being referred to as, Wellness Dentistry. So what exactly is Wellness Dentistry? And why would a dentist consider positioning his or her practice around it? To answer these questions and more is our guest Dr Mohammad Kamal. Dr Kamal completed his Pathology training at Harbor UCLA Medical Center in California, serving as a chief resident. He completed subspecialty fellowship training in Gastrointestinal and Liver Pathology at UCLA and he is board certified in Anatomic Pathology. Dr. Kamal served as Medical Director of LabCorp's Dianon Laboratory and as Chief Medical Officer for PLUS Diagnostics. Thanks to our episode sponsors: Ivoclar - https://www.ivoclar.com/ NSK America - https://www.nskdental.com/

Today's Guest Rebekah Taylor, M.A. CCC-SLP, is a licensed Speech-Language Pathologist specializing in Early Intervention (EI) and Complex Communication Needs (CCN) including Augmentative and Alternative Communication (AAC). Rebekah has enjoyed a rather diverse career background, from a child-care centre to the Anatomic Pathology department at Children's Hospital Los Angeles before beginning her career as an SLP. She draws upon every experience that has led her to this profession.  Throughout her work, Rebekah has developed a passion for supporting children and their families through what can sometimes be very emotional and frustrating experiences. She has completed the Leadership Education in Neurodevelopmental Disabilities (LEND) program with USC's UCEDD and has worked in a variety of pediatric settings including an interdisciplinary clinic, private practice, and schools in the US, as well as in schools and clinics within the National Health Service in England. These experiences have provided opportunities to understand a range of cultures, how communities and environments influence the growth of a child, and how to help a child feel secure and confident in their ability to communicate and participate in their world.  About Dr. Raj Dr Raj is a quadruple board certified physician and associate professor at the University of Southern California. He was a co-host on the TNT series Chasing the Cure with Ann Curry, a regular on the TV Show The Doctors for the past 7 seasons and has a weekly medical segment on ABC news Los Angeles. More from Dr. Raj www.BeyondThePearls.net The Dr. Raj Podcast Dr. Raj on Twitter Dr. Raj on Instagram Want more board review content? USMLE Step 1 Ad-Free Bundle Crush Step 1 Step 2 Secrets Beyond the Pearls The Dr. Raj Podcast Beyond the Pearls Premium USMLE Step 3 Review MedPrepTGo Step 1 Questions Learn more about your ad choices. Visit megaphone.fm/adchoices

Communicating imperative diagnoses effectively can often be a daunting challenge. It's a crucial and delicate step that takes practice and know-how to do well and can be one of the most important actions taken with patients. That's why a panel of experts have gotten together to discuss the current practices, gaps, and best practices for communication of urgent and significant/unexpected diagnoses in anatomic pathology.The Promoting Diagnostic Excellence by Improving the Communication of Urgent and Unexpected Diagnoses in Anatomic Pathology podcast is designed to support the collaboration with clinical partners as well as to notice actionable opportunities where the communication of urgent and significant/unexpected diagnoses in anatomic pathology may be improved.You will learn to:Understand current guidelines and practices for communication of urgent and unexpected diagnosis in anatomic pathology. Discuss high-priority communication barriers.Discuss best practices and recommendations for effective and timely communication of urgent and significant/unexpected diagnoses. 

Welcome to the Plant-Based Canada Podcast. In this episode we are joined by Dr. Prashant Jani to chat about his experiences in surgical pathology to community initiatives, including a food truck.Dr. Prashant Jani is a Pathologist and Associate Professor at Northern Ontario School of Medicine in Thunder Bay, Ontario, Canada.He completed his MBBS (1994) and MD (1997) from Pune University, India. He then came to Canada and completed a residency in Anatomic Pathology, and FRCPC, from the University of Toronto, Ontario, Canada (2001-2005). Dr. Jani is the inaugural Clinical Sciences Division Faculty Wellness Lead at Northern Ontario Cancer Research Centre, in Thunder Bay, Ontario, Canada. He has been practicing as a Pathologist and an Associate Professor of Pathology for the past 15 years and has been dedicated to promoting wellness for over 25 years. More specifically, he is a dedicated yoga instructor who has provided mental, physical and spiritual well-being in Thunder Bay for nearly two decades.Dr. Jani is the founder of the Superior Yoga Festival, Festival of India, Festival of Colours and Superior Veg Fest in Thunder Bay.  He has launched a volunteer-run, low-cost vegetarian meal delivery service out of the Vedic Cultural Centre, and expanded this to include a food truck. Lastly, Dr. Jani has established NovaCare Health and Wellness Centre in Thunder Bay to rehabilitate patients with chronic diseases. In this episode we discuss:Dr. Jani's plant-based journeyTypical day, plus tools and techniques in pathology Advocacy efforts and initiatives through the Vedic Cultural CentreTake home messageEpisode Resources:Festival of Colours Vedic Cultural CentreNova Care Health and WellnessFestival of IndiaDr. Prashant Jani's Socials:InstagramYouTubeTalk With Your Doc FacebookPlant-Based Canada's Socials:InstagramFacebook WebsiteX / Twitter: @PBC_orgBonus PromotionCheck out University of Guelph's online Plant-Based Nutrition Certificate. Each 4-week course will guide you through essential plant-based topics including nutritional benefits, disease prevention, and environmental impacts. You can also customize your learning with unique courses such as Plant-Based Diets for Athletes and Implementing a Plant-Based Diet at Home. As the first university-level plant-based certificate in Canada, you'll explore current research, learn from leading industry experts, and join a community of like-minded people. Use our exclusive discount code PBC2024 to save 10% on all Plant-Based Nutrition Certificate courses. www.uoguel.ph/pbn.Thank you for tuning in! Make sure to subscribe to the Plant-Based Canada Podcast so you get notified when new episodes are published. This episode was hosted by Stephanie Nishi RD, PhD.Support the Show.

Dr. Amy Durham, Professor and Assistant Dean at the University of Pennsylvania, joins Dr. Andy Roark on the Cone of Shame podcast to discuss PennVet's new active learning and learner centered curriculum. Together they dive into the driving factors behind this decision and what it's meant to students, faculty and the veterinary industry. LINKS PennVet Article on Curriculum: https://www.vet.upenn.edu/about/news-room/bellwether/bellwether-magazine/bellwether-spring-2023/educating-a-21st-century-veterinarian AAHA Article on Curriculum: Penn Vet transitions from discipline-based to fully integrated curriculum (aaha.org) Today's Veterinary Business Article: https://todaysveterinarybusiness.com/penn-vet-curriculum-121823/?oly_enc_id=5467B7086134E1Y Competency-Based Veterinary Education: https://www.aavmc.org/programs/cbve/ Uncharted Veterinary Conference: https://unchartedvet.com/uvc-april-2024/ Uncharted on the Road: https://unchartedvet.com/on-the-road/ Charming the Angry Client Course: https://drandyroark.com/charming-the-angry-client/ Dr. Andy Roark Swag: https://drandyroark.com/store/ ABOUT OUR GUEST Dr. Amy Durham is a Professor of Anatomic Pathology and Assistant Dean for Education at the University of Pennsylvania School of Veterinary Medicine. She went to Penn for vet school (class of 2005), did a residency in anatomic pathology at Penn, and then have stayed as a faculty member in the Department of Pathobiology. She became the assistant Dean for Education a couple of years ago, and is currently completing an MSEd in medical education.

It cannot be overstated how important it is for the dentist to perform regular oral cancer exams on all patients. We've heard it many times, "early detection of cancer is critical for a favorable prognosis." In today's episode we'll be specifically talking about the rise in throat cancer and the dentist's role in safeguarding patients against this insidious and potentially deadly disease. To tell us more about it is our guest, Dr Mohammad Kamal. Dr Kamal completed his Pathology training at Harbor UCLA Medical Center in California, serving as a chief resident. He completed subspecialty fellowship training in Gastrointestinal and Liver Pathology at UCLA and he is board certified in Anatomic Pathology. Dr. Kamal served as Medical Director of LabCorp's Dianon Laboratory and as Chief Medical Officer for PLUS Diagnostics. Thanks to our episode sponsors: Philips Oral Healthcare - https://www.philipsoralhealthcare.com/ VOCO America - https://www.voco.dental/us/

In the wake of my father's recent cancer diagnosis, my focus has sharpened on the critical realm of early cancer detection. This unexpected event injected a surge of urgency into my unyielding quest for preventive wellness, leading me back to the brilliant Dr. Ahvie Herskowitz. Embark on a journey into preventive health as I reunite with Dr. Ahvie, the founder of Anatara Medicine, one of the most comprehensive IV treatment centers in Northern California. The multidisciplinary integrative center in San Francisco treats some of the most difficult chronic health conditions using a unique integrative approach and a host of modern medical technologies and tools. Dr. Ahvie is a former Clinical Professor of Medicine at UC San Francisco (UCSF) and the personal physician to some of the Bay Area's top biohackers, celebrities, actors, and longevity enthusiasts, along with a wide range of patients looking for eradication of issues like mold, spike protein, fungus, viral particles, and much more. His training includes a medical degree from The Albert Einstein College of Medicine and a Chief Residency in Anatomic Pathology and Internal Medicine, followed by fellowship training in cardiology at The Johns Hopkins Medical Center.  During his 12 years at Johns Hopkins, Dr. Ahvie was co-appointed in the Departments of Medicine and Molecular Immunology and Microbiology. His clinical responsibilities were complemented by directing a multidisciplinary NIH-sponsored research team in the study of molecular immunological and genomic mechanisms of inflammation and cell injury, autoimmunity, transplantation, congestive heart failure, and myocarditis. Today, Dr. Ahvie is back to impart his wealth of knowledge on colon cancer, spanning early detection methods, cancer screening, preventive remedies, and the vital role lifestyle and diet play in managing and preventing this condition. This episode promises a thought-provoking journey into the intricacies of colon health and its profound implications for overall well-being. Full show notes: https://bengreenfieldlife.com/cancerepisode Episode Sponsors: Essentia: Save an additional $100 on your mattress  with code BENVIP at myessentia.com/bengreenfield. LMNT: Go to DrinkLMNT.com/BenGreenfield to get a free gift with your purchase! Calroy: Visit calroy.com/ben save 20% when you bundle a 3-month supply of Arterosil HP. KetoMed: Visit ketomed.com/ben use code Ben40 for $40.00 off, free shipping, and no tax. FUM: Head to tryfum.com/BEN and use code BEN to save an additional 10% off.See omnystudio.com/listener for privacy information.

Dr. Steven Quay is the founder of Seattle-based Atossa Therapeutics Inc., established in 2009. Prior to his work at Atossa, he served as Chairman of the Board, President and Chief Executive Officer of MDRNA, Inc., a biotechnology company focused on the development and commercialization of RNAi-based therapeutic products, from August 2000 to May 2008, and as its Chief Scientific Officer until November 30, 2008 (MDRNA, Inc. was formerly known as Nastech Pharmaceutical Company Inc. and is currently known as Marina Biotech, Inc.). Dr. Quay is certified in Anatomic Pathology with the American Board of Pathology, completed both an internship and residency in anatomic pathology at Massachusetts General Hospital, a Harvard Medical School teaching hospital, and is a former faculty member of the Department of Pathology, Stanford University School of Medicine.   Dr. Quay is a named inventor on 76 U.S. patents, 108 pending patent applications and is a named inventor on patents covering five pharmaceutical products that have been approved by the U.S. Food and Drug Administration. He received an M.D. in 1977 and a Ph.D. in 1975 from the University of Michigan Medical School. He also received his B.A. degree in biology, chemistry and mathematics from Western Michigan University in 1971. Dr. Quay is a member of the American Society of Investigative Pathology, the Association of Molecular Pathology, the Society for Laboratory Automation and Screening and the Association of Pathology Informatics.

Have you ever considered the critical link between oral health and your overall well-being, particularly in relation to oropharyngeal cancer? Are you aware of how the Human Papillomavirus (HPV) could be silently impacting your health, and the vital role early detection plays? In this enlightening episode of me&my health up, host Anthony Hartcher is joined by Dr. Mohammad Kamal, a renowned expert in pathology, to delve deep into the intricate world of HPV and its undeniable connection to oropharyngeal cancer. Dr. Kamal sheds light on the silent nature of HPV, explaining how this prevalent virus can reside in the body for years without showing any symptoms, yet have a profound impact on one's health. Discover the importance of early detection and the proactive steps you can take to protect yourself and your loved ones. Dr. Kamal emphasises the crucial role dental professionals play in identifying early signs of oropharyngeal cancer, highlighting the need for regular dental check-ups and open conversations about HPV and its associated risks. Tune in to empower yourself with knowledge and learn why HPV awareness is more crucial than ever. Don't miss out on this opportunity to take a proactive stance in your health journey and contribute to the global fight against oropharyngeal cancer.  About Dr, Mohammad Kamal:  Dr. Mohammad Kamal holds the esteemed positions of Founder and Chief Executive Officer at Omnipathology. He is board certified in Anatomic Pathology and is renowned for his subspecialty expertise in Gastrointestinal and Liver Pathology. Completed his Pathology training at Harbor UCLA Medical Center in Torrance, California, where he also served as a chief resident. He further honed his skills and knowledge through subspecialty fellowship training in Gastrointestinal and Liver Pathology at UCLA. Dr. Kamal has an extensive and impressive career, having managed large national pathology laboratories. He served as the Medical Director of LabCorp's Dianon Laboratory and as Chief Medical Officer for PLUS Diagnostics. He is recognized as an expert in laboratory quality, with a stellar track record of developing quality systems and guiding laboratories to achieve CLIA, CAP, and New York State accreditations. Dr. Kamal has a particular interest in colon cancer, Barrett's esophagus, and inflammatory bowel disease. He is a frequent lecturer at medical schools and conferences, both in the United States and internationally. His commitment to education and healthcare is evident through his voluntary work as a Clinical Assistant Professor of Pathology at UCLA. Connect with Dr. Mohammad Kamal and OmniPathology:  Website:    https://www.omnipathology.com/ LinkedIn:    https://www.linkedin.com/company/omnipathology-medical-solutions/ Facebook: https://www.facebook.com/OmniPathology/ Instagram: https://www.instagram.com/omnipathology/ Youtube:    https://www.youtube.com/@OmniPathology  About mePodcast DisclaimerAny information, advice, opinions or statements within it do not constitute medical, health care or other professional advice, and are provided for general information purposes only. All care is taken in the preparation of the information in this Podcast. [Connected Wellness Pty Ltd] operating under the brand of “me&my health up”..click here for moreSupport the show

On today's episode, meet Dr. Dara Aisner, MD, PhD. Dr. Aisner is Associate Professor at the University of Colorado School of Medicine and Director of the Colorado Molecular Correlates Laboratory. After her undergraduate work at Vanderbilt, Dr. Aisner completed her MD/PHD combined degree program at the University of Texas Southwestern Medical School and Graduate School of Biomedical Sciences. She pursued training in Anatomic Pathology at the National Institutes of Health, and went on to two fellowships in Surgical Pathology and Molecular Genetic Pathology at the University of Pennsylvania.

Joining us is Dr. Mohammad Kamal, a renowned pathologist, CEO, and Founder of OMNIPathology Lab. With an impressive track record as a sought-after international educator, Dr. Kamal has shared his expertise with audiences worldwide. His commitment to advancing the field of pathology and his passion for education have earned him a well-deserved reputation as a trusted authority.  Dr. Mohammad Kamal is an accomplished pathologist and artist. With a background in Pathology training at Harbor UCLA Medical Center and a subspecialty fellowship in Gastrointestinal and Liver Pathology at UCLA, he is board certified in Anatomic Pathology. Dr. Kamal has amassed extensive experience in managing national pathology laboratories, holding significant positions such as Executive Medical Director of LabCorp's Dianon Laboratory and Chief Medical Officer for PLUS Diagnostics. Dr. Kamal is widely recognized as an expert in his field and regularly shares his knowledge and insights as a lecturer at medical schools and conferences both in the United States and internationally. He also served as a volunteer clinical Assistant Professor of Pathology at UCLA. While excelling in his role as a pathologist, Dr. Kamal has nurtured his artistic side through photography. His art captures captivating microscopic images derived from his daily review of cases, offering a unique fusion of scientific and artistic interpretation. These images provide a different perspective, reminding him of the human stories behind each sample and the hidden beauty found within microscopic views. Through his remarkable journey as a pathologist and artist, Dr. Kamal continues to inspire others and push the boundaries of both science and art.  

Artificial intelligence is one of the most significant trends in most parts of society. Increasingly, oncologists and lung cancer researchers are including AI in research and patient care. In this episode of Lung Cancer Considered, host Dr. Narjust Florez leads a discussion of this compelling technology, focusing on its promise and limitations. Guests: Dr. Sanja Dacic, MD, PhD, MSc, an internationally renowned and highly accomplished leader in anatomic pathology and the Vice Chair and Director of Anatomic Pathology in the Department of Pathology at Yale School of Medicine. She currently serves as president of the Pulmonary Pathology Society. Dr. Fabio Ynoe de Moraes, MD, PhD, MBA - an Associate Professor and clinical investigator in radiation and global oncology at the Queen's University and Kingston Health Sciences Centre, Kingston, ON, Canada. Dr Moraes has more than one hundred published peer-reviewed articles (i.e., NEJM, Lancet Oncology, Nature Medicine, Nature Biotechnology) and holds a PhD in Health Sciences (Oncology) and post graduate degree in artificial intelligence and machine learning and is one of the upcoming IASLC 2024 WCLC Chairs.

Today my guest is Pathologist Dr Sheela Upreti Dr Upreti is the author of From Specimen to Sign Out, Anatomic Pathology Explained, which aims to provide accessible and helpful information for health professionals, including junior pathology residents, as well as potentially benefiting patients. She discusses her experience and insights on the role of pathologists in multidisciplinary meetings, emphasizing the importance of communication and collaboration in these meetings, where pathologists can provide valuable insights and suggest further actions based on their access to information and ancillary tests. Dr Upreti also highlights the impact of clinical history on the diagnostic process and dispels the misconception that providing pathologists with too much clinical information may bias their diagnosis. She discusses the limited exposure to pathology in medical school and the declining number of medical students going into pathology, hoping that her book will help reverse this trend.  Finally, she discusses the future of pathology education, focusing on technology, collaboration, and the potential of virtual reality in simulating pathology procedures and providing access to different types of specimens.  Links for this episode: Pathology 101 for Tissue Image Analysis  Health Podcast Network  LabVine Learning The ConfLab from LabVine Dress A Med scrubs   From Specimen to Sign-Out: Anatomic Pathology Explained Royal College Of Pathologists of Australasia   People of Pathology Podcast: Twitter Instagram

Whenever a goat dies, we always want to know why. But the only way to know for sure is to get a necropsy, and that's what we're talking about in this episode.I was convinced of the importance of necropsies after owning goats for only five years when a seemingly healthy doe suddenly started screaming and was dead an hour later. Without the necropsy, we never would have known that she had died from Tyzzer's disease, which is not normally seen in goats.Dr. Jonathan Samuelson, Clinical Assistant Professor of Anatomic Pathology in the Veterinary Diagnostic Laboratory at the University of Illinois College of Veterinary Medicine, talks about what a necropsy is, what it can tell us, and what it can't.We talk about gross necropsy, histopathology, electron microscopy, and other aspects of a necropsy that can tell us why our goat died about 85% of the time, according to Dr. Samuelson. But even if the necropsy can't pinpoint the exact cause of death, it can rule out causes, which can also be helpful.See full show notes here >> https://thriftyhomesteader.com/goat-necropsy/To see the most recent episodes, visit  ForTheLoveOfGoats.comWant to support the content you love?Head over to -- https://thrifty-homesteader.ck.page/products/love-goats-tip-jarThanks for listening!No one ever said raising goats was easy, but it doesn't have to cost a fortune or drive you crazy! You just need the right information. Click here to learn more about our Goats 365 membership. Or see my other goat courses in Thrifty Homesteader Academy.

In this episode of our podcast, we have the pleasure of speaking with the accomplished and passionate Dr. Andrea Deyrup. As a Professor of Pathology at Duke University School of Medicine, Dr. Deyrup is an expert in her field, serving as the course director for the medical school pathology course and co-editor of Robbins Essential Pathology and of Robbins and Kumar Basic Pathology. But Dr. Deyrup's work goes beyond academia. She is a dedicated advocate for anti-racism in medicine, using her thriving Pathology website and YouTube channel to share information and raise awareness about the intersection of race and healthcare. During our conversation, we delve into Dr. Deyrup's impressive educational background, from her undergraduate studies in Ecology and Evolutionary Biology at Princeton University to her Ph.D. in Pathology at the University of Chicago and her M.D. from the Pritzker School of Medicine at the same university. We also discuss her residency in Anatomic Pathology at the University of Chicago and her fellowship in soft tissue pathology at Emory University. Join us as we learn from Dr. Deyrup's wealth of knowledge and passion for pathology and anti-racism in medicine. This is an episode you won't want to miss. Episode produced by: Isabelle Tan, Lauren Hekman Episode recording date: 01/23/23 www.medicuspodcast.com | medicuspodcast@gmail.com | Donate: http://bit.ly/MedicusDonate --- Send in a voice message: https://podcasters.spotify.com/pod/show/medicus/message

Are you ready for Medical Laboratory Professionals Week?  Our annual celebration of pathologists and medical laboratory professionals begins April 23, 2023, and this year's theme is Saved by the Lab, a play on the popular sitcom from the 1990s, Saved by the Bell. In honor of Zack Morris and friends from Bayside High, we're revisiting the ‘90s to explore what was going on in the world—and the world of laboratory medicine. On this LIVE episode of Inside the Lab, your host, Ms. Kelly Swails, MLS(ASCP), is joined by Dr. Robert A. Goulart, MD, MASCP, FCAP, Associate Chief of Anatomic Pathology and Director of Quality and Patient Safety at the University of Massachusetts Memorial Health System and President-Elect of ASCP, Mr. Sean McNair, MPH, Cytology Education Coordinator at the Memorial Sloan Kettering Cancer Center and Program Director for the Cytology Training Program at Hunter College, Ms. Stephanie Y. Whitehead, MPH, MBA, MLS(ASCP), Executive Director of Pathology and Laboratory Services at University Health System in San Antonio, Texas, and Chair Elect for the Council of Laboratory Professionals, and Dr. Constantine Kanakis, MD, MSc, MLS(ASCP), Resident Physician at Loyola Medicine in Chicago and Member of the ASCP Patient Champions Advisory Board, for a ‘90s trivia showdown. Our panelists answer questions about ‘90s pop culture, including the highest grossing movies, chart-topping music and hottest toys of the decade.Dr. Goulart, Mr. McNair, Ms. Whitehead and Dr. Kanakis also test their knowledge of noteworthy lab news from the ‘90s. Listen in to find out which of our panelists took home the coveted prize, a tote bag filled with Saved by the Lab gear! Topics Covered · Popular ‘90s trends such as the Tamagotchi, Tickle Me Elmo, Harry Potter and reality television· ‘90s pop culture trivia, e.g.: the most-watched episode of TV, highest grossing movie and chart-topping music of the decade· Lab-specific ‘90s trivia like when ASCP elected a laboratory professional to the Board of Directors for the first time or how many lab professionals were working in the US at that time· Noteworthy laboratory news from the ‘90s, including Marie Gatscha's testimony to Congress on behalf of ASCP, the revision of the WHO Blue Book on bone tumors, and trastuzumab's impact on breast cancer treatment Connect with ASCPASCPASCP on FacebookASCP on InstagramASCP on Twitter Connect with Dr. GoulartDr. Goulart on LinkedIn Connect with Mr. McNairMr. McNair on LinkedIn Connect with Ms. WhiteheadMs. Whitehead on LinkedInMs. Whitehead on TwitterMs. Whitehead on Instagram Connect with Dr. KanakisDr. Kanakis on LinkedInDr. Kanakis on TwitterDr. Kanakis at Loyola Pathology Connect with Ms. SwailsMs. Swails on Twitter ResourcesASCP Lab Week ResourcesInside the Lab in the ASCP Store 

In this episode of “Lab Medicine Rounds,” Justin Kreuter, M.D., sits down with Shane Ferraro, M.H.S., PA(ASCP), an assistant supervisor of pathologists' assistants in the Division of Anatomic Pathology at Mayo Clinic in Rochester, Minnesota, to talk about the important innovation of 3D scanning in pathology. Timestamps:0:00 Intro00:54 Why is 3D scanning an important innovation in pathology?02:51 Are there certain activities you can do with the audience that you weren't able to do before? Are there certain insights you are hearing from the learners when you are doing that kind of approach?03:40 What do you think is important for our audience to understand about 3D scanning?06:12 What are some of the practicalities for implementing 3D scanning in a pathology practice?08:23 Are there different teams that you are interacting with outside of pathology that is helping to make some bridges between pathology and other clinical departments?09:22 In pathology, it sounds like it got started with forensic pathologists, and now it's being brought out to the surgical practice?10:12 How long does it take to scan some tissue? Is it relatively quick or like a day-long process?11:40 Is this thought to replace surgical pathology photography in the next 5-10 years?12:29 Where do you see this innovation going over these next 5-10 years?14:46 Outro

Today my guests are Robert Lott and Joshua Greenlee from the Anatomic Pathology Patient Interest Association  What we discuss with Robert and Josh: How they each got into the histotechnology field How they became involved in training programs Why they decided to move from the clinical lab into industry The Anatomic Patient Interest Association (APPIA) and what it does How the TOPS program was developed and why it is important How to become a member of APPIA Links for this episode: Health Podcast Network  LabVine Learning The ConfLab from LabVine Dress A Med scrubs   Anatomic Pathology Patient Interest Association APPIA on LinkedIn APPIA on Twitter TOPS Program National Society for Histotechnology   People of Pathology Podcast: Twitter Instagram

Taylor Harris is a Pathologists' Assistant and proudly, has the honor of being the first African American/Black person to earn a Masters of Anatomic Pathology from Tulane School of Medicine. Taylor claims both West Tennessee and Central Illinois as home. Taylor obtained a BA in Biopsychology from McKendree University. Her journey in medicine/healthcare began as a Certified Nursing Assistant having worked ICU and Med/Surg. Following undergraduate, she shifted into social services as a Residential Counselor for abused/neglected youth. Taylor eventually transitioned back into medicine by way of histology which led her to pathology. Currently, Taylor promotes Pathology and shares her experience as a Pathologists' Assistant on social media.  Instagram: @path_a_tay Taylor Harris (@path_a_tay) • Instagram photos and videosYouTube: PathA Tay https://youtu.be/_GZpDWGa6iA LinkedIn: www.linkedin.com/in/taylor-dubose-harris-pathassist

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, sits down with Joaquin Garcia, M.D., chair of Mayo Clinic's Division of Anatomic Pathology and digital pathology program to discuss how the advent of digital pathology is changing patient care at Mayo Clinic.

Podcast Editor, Tracy Carlson, interviews author William Siska about the article, "Scientific and Regulatory Policy Committee Points to Consider: Integration of Clinical Pathology Data With Anatomic Pathology Data in Nonclinical Toxicology Studies" which can currently be found in  Volume 50, Issue 6 of Toxicologic Pathology. Click here to read the article

I know...dialectical behavior therapy sounds complicated - but it is DBT for short, and Dr. Osmond does a great job of summarizing a key concept - wise mind being a combo of rational mind and emotion mind. This is an important concept for us all, relevant to home life and any decision-making task, including diagnostic work for physicians. DBT (first brought up to me by David Caruso in a prior episode) can also give insights into burnout (consider listening in to Michi Shinohara, if you haven't yet!). Dr. Allison Osmond is an Assistant Professor of Pathology and Laboratory Medicine at the University of Saskatchewan. Dr. Osmond completed residency in Anatomic Pathology at Western University in London, Ontario Canada in 2015, followed by a Surgical Pathology Fellowship at Western, with a focus in gastrointestinal pathology. She then worked in a general Anatomical Pathology practice for one year and then completed Dermatopathology fellowship at the University of Toronto in 2018. Dr. Osmond has a keen interests include digital pathology and teaching dermatopathology to residents and medical students at the microscope and in particular via the global #dermpath Twitter community. You can find her on Twitter @redsnapperpath. Her colleague. Dr. Katelynn Campbell is on Twitter @KCampbellMD. 

Dr. Pouya Jamshidi was born and raised in Tehran, Iran, where he studied Russian literature and classical music. He played the Trumpet and French Horn in the Tehran Philharmonic Orchestra, advancing to becoming the youngest Assistant Conductor of the Orchestra at the age of 19. Upon immigration to the US, Dr. Jamshidi majored in Cognitive Science and Neuroscience at the University of California-San Diego, where he also conducted neuroscience research. He earned his medical degree from Weill Cornell Medical College in New York City and finished a year of internship in Obstetrics and Gynecology at Weill Cornell New York-Presbyterian Hospital. He then pursued a year of postdoctoral fellowship at the Mesulam Center for Cognitive Neurology and Alzheimer's Disease at Northwestern University, Feinberg School of Medicine. Dr. Jamshidi completed his residency in Anatomic Pathology at University of Chicago- NorthShore. He is now a 2nd-year neuropathology fellow at Northwestern Memorial Hospital in Chicago. Dr. Jamshidi loves spending time with his wife, two sons and his adopted dog, Moca, enjoys international cuisines, and listening to classical music and opera.   Twitter: Pjamshidi_MDhttps://ucsdnews.ucsd.edu/archive/thisweek/2008/05/19_ensemble_con_brio.asp   

***Please excuse my voice - I recorded this towards the end of a several weeks-long illness!***What is the difference between late medieval and early Renaissance Italian painting? Dr. Philip LeBoit knows! (find out how!) (I still don't know the actual answer....) Dr. Philip LeBoit is Professor of Pathology and Dermatology as well as Division Chief of the Dermatopathology Service at the University of California, San Francisco. He founded the UCSF Dermatopathology and Oral Pathology Service in 1987. He trained in Anatomic Pathology at University of California, San Francisco and then in Dermatopathology at New York University under Dr. Bernard Ackerman and at New York Hospital-Cornell Medical Center under Dr. N. Scott McNutt. He has written several academic textbooks, including one of my favorites with Dr. Guido Massi, Histologic Diagnosis of Nevi and Melanoma. He was editor-in-chief of the American Journal of Dermatopathology from 1997-2006 and an associate editor of the Journal of Investigative Dermatology.

Dr. Lewis Hassell is a pathologist and Director of Anatomic Pathology at The University of Oklahoma Health Sciences Center. He joins Beyond the Scope to introduce the Open Pathology Education Network (OPEN) and discuss the challenges currently facing the global pathology workforce. OPEN is a platform that aims to provide remote and digital education to pathologists in underserved areas of the world; they recently launched the first pilot programs in Vietnam. Dr. Hassell also shares his insights on how learnings from the COVID 19 pandemic are transforming the way we educate the next generation of pathologists. To become involved or learn more about OPEN, please email Dr. Hassell directly: lewis-hassell@ouhsc.edu

Alvin and German conduct a great conversation with SUNY Professor Emeritus of Pathology, Gregory A Threatte, '69. After Colgate, he received his medical degree from the SUNY, Upstate MedicalUniversity in 1973. He served an internship in Medicine at Upstate, and a residency in Anatomic Pathology at the Western Pennsylvania Hospital in Pittsburgh. He was a Resident and Chief Resident inClinical Pathology at the University of California, San Francisco and then a Hematology research fellow at the Lawrence Berkeley National Laboratory. He was appointed to the faculty as an Assistant Professor of Pathology at Georgetown University in 1981 In 1986 he returned to Upstate Medical University as the Deputy to the President for Minority Affairs and Associate Professor, later rising to the rank of Professor and then Chair. He established the Diversity programming that led to Upstate being cited by Black Issues in Higher Education for being the 10th leading producer of African American Physicians in 1994. He has received the SUNY President's Award for the Advancement of Affirmative Action, the SUNY President's Award for Excellence in Teaching, and numerous other teaching awards. He served for 9 years on the Board of Trustees of Colgate University.

Timestamps:00:00 Intro01:04 Why is molecular information important for you in your practice to integrate into anatomic pathology? 06:22 How did you recognize that molecular information was really a critical competency for you to develop as an anatomic pathologist? 09:51 Do you find yourself going to different sessions when you go to conferences, or are you specifically paying attention to ones that have a molecular thread through them?11:23 How do you recommend that we all continue to embrace new opportunities in clinical practice? 13:01 We are talking about how molecular has come down the pike and been something new that's been added on to your practice. Is this importance of channels of communication, how has it changed in recent years?14:45 Outro

Dr. Taofeek Owonikoko is a Professor and Vice Chair for Faculty Development in the Department of Hematology and Medical Oncology at Emory University, Atlanta. He is also a Georgia Research Alliance Distinguished Cancer Scientist. Owonikoko received his medical degree from the Obafemi Awolowo University, Ile-Ife Nigeria in 1991 and a doctoral degree in Anatomic Pathology from the Heinrich Heine University, Dusseldorf, Germany in 2000.  He has been on faculty at Emory University since 2008 and has focused on lung cancer, thyroid cancer as well as early phase drug development.

Dr. Brian Adkins is the Medical Director of Transfusion and Tissue Service at Children's Health Dallas and an Assistant Professor of Pathology at University of Texas Southwestern. He is board-certified in Anatomic Pathology and Clinical Pathology with subspecialty certification in Blood Banking/Transfusion Medicine and Hematopathology. Dr. Adkins has published multiple papers about Transgender health and was an invited speaker at the 2021 American Society for Clinical Pathology meeting to present on contemporary transfusion and cellular therapy in Transgender and Non-binary individuals Twitter:  Brian Adkins (@path_brian) / Twitter

Life hacks are tricks or shortcuts that make life easier and more efficient, like storing the roll of garbage bags at the bottom of your trash bin so the next bag is right there when you take out the trash.In the world of anatomic pathology, tissue and organ samples run through multiple processes to render a diagnosis, it's especially important that to stay organized and efficient. So, what life hacks can pathologists and medical laboratory scientists leverage to make our life in the anatomic pathology lab easier? What can  be more productive and precise? On this episode of Inside the Lab, our hosts Dr. Dan Milner and Ms. Kelly Swails are joined by Dr. Sarah Garner, PhD, MS, PA(ASCP), Director of the Pathologists' Assistant Program at Tulane University, Ms. Michelle Bell, HT(ASCP)CM, Applications Manager at Milestone Medical and 20-year veteran of laboratory management, and Dr. Jerad Gardner, MD, Dermatopathologist and Bone/Soft Tissue Pathologist at Geisinger Medical Labs, to share their best life hacks for anatomic pathology. Our panelists discuss their most effective workflow strategies, and describe how they optimize their time at the microscope to produce accurate results. They weigh in on the best ways to manage people and walk us through their top hacks for ensuring positive, active communication with clinical partners and colleagues. Listen in for best time management hacks and learn how they set priorities in their personal and professional lives. Topics Covered · Top technical and workflow hacks for anatomic pathology· Maintaining order in the absence of a barcoding system· Developing  a culture of appreciation in the anatomic pathology lab· Why time management is a challenge in the anatomic pathology lab· Strategies for optimizing time at the microscope and producing valuable results· Best practices for ensuring positive, active communication with clinical partners and colleagues inside and outside your institution· How our panelists navigate impromptu testing requests from clinicians· Dr. Garner, Ms. Bell, and Dr. Gardner's advice on achieving work-life balance Connect with ASCPASCPASCP on FacebookASCP on InstagramASCP on Twitter Connect with Dr. GarnerDr. Garner on Twitter Dr. Garner at Tulane Connect with Ms. BellMilestone Medical Ms. Bell on LinkedIn  Connect with Dr. GardnerDr. Gardner on Twitter Dr. Gardner at GeisingerConnect with Dr. Milner & Ms. SwailsDr. Milner on Twitter Ms. Swails on Twitter Resources  Daniel Pink's WHEN on Inside the Lab S2EP11 Inside the Lab in the ASCP Store 

Are you ready to get Nerdy? Mistress D. explores the science of what exactly makes us love BDSM. This episode explains the chemical reason we seem to feel our best when we play, and why it's so comfortable when we're done. This episode features a very juicy interview with Sir Phoenix Black, a Sadistic Male Dominant, who has an extensive background in Anatomic Pathology and BDSM. He enlightens us to the biochemical process that takes place in our bodies before, during, and after a BDSM session. He provides tips on how to safely explore your limits and enjoy your kink experience. Show Timestamps for ease of sharing: (1:28) - Show overview (4:00) - Sir Phoenix Black Introduction (7:00) - Why people get into BDSM (13:00) - What is Dom/sub-space (16:40) - The Euphoria of BDSM (17:55) - Trust opens the door to euphoria (19:00) - Sir Phoenix Black on Fireplay (21:03) - Pain-tolerance in Kink (29:22) - Initiating your Kink journey (31:30) - Inside Dom/sub-space (37:20) - Personalities perfect for kink (38:22) - What is Dom/sub Drop (50:15) - Your Kink, Your Journey (56:20) - Tips and Events from Sir Phoenix Black Guest Information - Sir Phoenix Black * Fetlife: Sir Phoenix Black * Instagram: @realphoenixblack The Fetish School Information Website: https://www.TheFetishSchool.com/ PayPal Donation: @thefetishschool Fetlife: The Fetish School Instagram: @thefetishschool

In addition to interpreting patient biopsies and signing out cases, pathologists perform a wide variety of functions - including intraoperative consultation or frozen section, presenting cases at tumor boards or other conferences, doing procedures, or assessing the adequacy from image guided biopsies. This is done in a wide variety of practice settings. Many times, it's done over a very large geographical area where the physical presence of a pathologist may be impractical or highly inconvenient. Our guest is Hannah Gilmore, MD, Chief of the Division of Anatomic Pathology at University Hospitals Case Medical Center in Cleveland. We're talking about the unique challenges and pain points pathologists face in the large hospital system covering a large geography. How can digital pathology help alleviate some of these challenges? What are specific applications that, if implemented, would give us immediate benefit? How can digital pathology make pathologists more productive - particularly in areas not strictly related to primary diagnostic activity?

Rajendra Singh is Professor of Dermatology and Pathology, Director of Dermatopathology, and Associate Chair of Digital Pathology at Northwell Health, New York, USA. He is also the Founder of PathPresenter Corporation. He can be found on Twitter at @mydermpath and @pathpresenter.Melanie Bois is Consultant in the Division of Anatomic Pathology and Assistant Professor of Laboratory Medicine and Pathology at Mayo Clinic, Rochester, Minnesota, USA. She can be found on Twitter at @MelanieBoisMD.Join us back on the tour bus on January 11, 2022, for the next stop in our two-episode, histopathology special!

Hi friends, this is Dr. Michael Williams and welcome to another episode of the diversify in path podcast. This podcast explores how investing in diversity can lead to a high return of investment in pathology and laboratory medicine by learning from the knowledge and experiences of diverse voices within in our field.  My next guest is Dr. Andrea DeyrupDr. Deyrup received her undergraduate degree from Princeton University in the Department of Ecology and Evolutionary Biology in 1991 before joining the University of Chicago for her Ph.D. (Pathology, 1997), M.D. (2000) and residency (Anatomic Pathology, 2000-2003). She completed her formal training in soft tissue pathology at Emory with Dr. Sharon Weiss and joined the faculty there in 2004. She has published extensively in the field of soft tissue and bone pathology.Since 2015, Dr. Deyrup's career has focused on medical education. At that time, she joined the faculty of the Duke Pathology Department as Course Director of the first-year medical school pathology course; in January of 2019, she was named the Director of Undergraduate Medical Education for the Pathology Department. She also serves on the Undergraduate Medical Education Council for the Association of Pathology Chairs, participated in the 2020-21 Duke Teaching for Equity Fellows Program and was a member of the Duke School of Medicine Health Professions Anti-Racism Task Force.  Dr. Deyrup is one of the co-editors of the new Robbins Pathology textbook, Essential Pathology and of the upcoming 11th edition of Robbins Basic Pathology. Dr. Deyrup is actively committed to antiracism efforts and to improving discussion of health disparities in medical education Twitter: @ATDeyrupMDPhDYoutube: https://www.youtube.com/channel/UC_C1NfzSg96ybalbjl8XydAWebsite: https://www.pathologycentral.org/

Dr. Omalu received his MB, BS [M.D.] degree from the University of Nigeria in 1991. He received his MPH [Masters in Public Health] degree in Epidemiology from University of Pittsburgh in 2004. He also received his MBA [Masters in Business Administration] degree from Carnegie Mellon University in 2008. Dr. Omalu holds four board certifications in Anatomic Pathology, Clinical Pathology, Forensic Pathology and Neuropathology. Dr. Omalu is also board certified in Medical Management and is a Certified Physician Executive [CPE]. Dr. Bennet Omalu, identified a disease he called Chronic Traumatic Encephalopathy [CTE] in the brains of deceased athletes and military veterans; and received the “Distinguished Service Award” in 2016, which is the highest award of the American Medical Association. In December 2015, Sony Pictures produced and released a major Hollywood film titled “Concussion” on Bennet's life and work. Will Smith played Dr. Omalu in the film. Bennet's memoir “Truth Doesn't Have a Side” was published in 2017 by Zondervan, HarperCollins. Dr. Bennet Omalu is currently the President and Medical Director of Bennet Omalu Pathology. --- Send in a voice message: https://podcasters.spotify.com/pod/show/mastermine-mrg/message

Hi Friends! Welcome to another episode of the diversify in path podcast.  This podcast explores how  investing in diversity  can lead to  a high return of investment in pathology and laboratory medicine by learning from the knowledge and experiences of  diverse voices within in our field. My next Guest is Dr. Michael Arnold MD PhDDr. Michael A. Arnold, is the Medical Director of Anatomic Pathology at Children's Hospital Colorado, and an Associate Professor of Pathology at the University of Colorado, in Denver, Colorado.  Dr. Arnold received a B.A. in molecular genetics from the University of Rochester (Rochester, NY), and  completed the medical scientist training program at the University of Texas Southwestern Medical Center at Dallas, receiving his Ph.D. in Genetics and Development for his work in the laboratory of Dr. Eric N. Olson. He completed residency training in Anatomic Pathology at the University of Texas Southwestern Medical Center at Dallas and the National Cancer Institute at the National Institutes of Health. While at the National Cancer Institute, he completed a research fellowship in ultrastructural pathology and pediatric tumor pathology with Dr. Maria Tsokos. Following his research fellowship, Dr. Arnold continued at Nationwide Children's Hospital where he completed a pediatric pathology fellowship. He became a faculty member at The Ohio State University and practiced at Nationwide Children's Hospital as a staff pathologist later becoming Director of Surgical Pathology.  He subsequently moved to Children's Hospital Colorado in 2019 to become the Medical Director of Anatomic Pathology, and is also currently the Pathology Informaticist for Children's Hospital Colorado.  In addition to his role as Medical Director of Anatomic Pathology, Dr. Arnold practices general pediatric surgical pathology, including autopsies, gastrointestinal biopsies and pediatric cancers. He has been active in the Soft Tissue Sarcoma group in Children's Oncology Group (COG) since participating in the Young Investigator program in 2014, mentored by Dr. Erin Rudzinski, and is now a central pathology reviewer for COG rhabdomyosarcoma clinical trials.  Dr. Arnold is a member of the College of American Pathologists (CAP), the United States and Canadian Academy of Pathology (USCAP), and the Society for Pediatric Pathology (SPP). He serves on the CAP Virtual Lecture Series Steering Committee, and the SPP Informatics and Communication Committee. In 2020, he was elected to serve a two-year term on the EPIC Beaker Pathology Steering Board. Dr. Arnold has authored over 60 peer reviewed manuscripts, as well as invited reviews and a book chapter on pediatric bone tumors.  He lectures on various topics in pediatric pathology, including his April 2020 lecture on pediatric tumors for the CAP Virtual Lecture Series. He is also the director of the Pediatric Pathology module in PathElective.com Michael A. Arnold, MD, PhDDepartment of Pathology and Laboratory MedicineChildren's Hospital Colorado13123 East 16th Avenue, B120Aurora CO, 80045720-777-2517Michael.Arnold@ChildrensColorado.orgTwitter: @MArnold_PedPathWebsite:  Michael Arnold | Children's Hospital Colorado (childrenscolorado.org)Website: PathElectivePodcast : ‎The PathPod Podcast on Apple Podcasts| On multiple podcasting platforms 

Hi Friends! Welcome to another episode of the diversify in path podcast. This podcast explores how  investing in diversity  can lead to  a high return of investment in pathology and laboratory medicine by learning from the knowledge and experiences of  diverse voices within in our field. My next guest is Dr. Evita Henderson -Jackson.Evita B. Henderson-Jackson, MD is an American Board of Pathology certified pathologist in Anatomic/Clinical Pathology and Cytopathology working as an Associate member in the Department of Anatomic Pathology at Moffitt Cancer Center, Tampa FL. She has expertise in the areas of bone and soft tissue pathology and cytopathology.  She is the pathology residency program director at the University Of South Florida Morsani College Of Medicine (USF MCOM). She received her Doctor of Medicine at the Medical University of South Carolina in Charleston. She completed her pathology residency training at University of South Florida, as well as a surgical oncologic pathology fellowship and cytopathology fellowship at Moffitt Cancer Center. As a clinical educator she is passionate and constantly involved in medical education of students, residents, fellows and clinicians. Her research efforts focus on the pathogenesis of soft tissue sarcomas and the identification of diagnostic, prognostic and predictive biomarkers.  She has over 40 peer-reviewed publications and five book chapters. She collaborates with clinicians and pathologists on quality improvement initiatives; diversity, equity and inclusion initiatives; education initiatives (curriculum development, assessment, milestones, etc.) and digital pathology efforts.  Outside of her clinical and teaching duties, she enjoys spending time with her children and playing soccer.Twitter: @EHJPathDivaWebsite: Residency | USF Health

On Episode 8 of the Stroke Alert Podcast, host Dr. Negar Asdaghi highlights two articles from the September 2021 issue of Stroke: “Risk of Fractures in Stroke Patients Treated With a Selective Serotonin Reuptake Inhibitor” and “Carotid Plaques From Symptomatic Patients Are Characterized by Local Increase in Xanthine Oxidase Expression.” She also interviews Drs. Jukka Putaala and Markku Kaste about their article “Should Tenecteplase be Given in Clinical Practice for Acute Ischemic Stroke Thrombolysis?”. Dr. Negar Asdaghi:         1) Are we ready to say goodbye to our old friend alteplase and replace it with a new one, tenecteplase, for acute stroke thrombolysis? 2) Does treatment of depression with SSRIs increase the risk of fractures in stroke patients? 3) When it comes to carotid intervention, should we continue offering treatment based on the degree of luminal stenosis, or are there better biomarkers in the horizon? These are some of the questions that we'll tackle in today's podcast. We're covering the best in Stroke. Stay with us. Dr. Negar Asdaghi:         Welcome back to Stroke Alert Podcast. My name is Negar Asdaghi. I'm an Associate Professor of Neurology at the University of Miami Miller School of Medicine and your host for the monthly Stroke Alert Podcast. For the September 2021 podcast, we have an exciting program where we discuss some of the controversies in stroke therapies. The September issue also contains a Focused Update with a set of articles and comprehensive reviews on the topic of genetics and stroke, organized by Professor Martin Dichgans, which I encourage you to review in addition to our podcast today. Later in today's podcast, I have the pleasure of interviewing Drs. Putaala and Kaste, from Helsinki Institute, to help us with a burning question of whether there's enough evidence now to use tenecteplase instead of alteplase for ischemic stroke thrombolysis. But first with these two articles. Dr. Negar Asdaghi:         Over a third of stroke survivors either have depressive symptoms or a formal diagnosis of depression. Selective serotonin reuptake inhibitors, or SSRIs, are the mainstay of depression treatment and the most common antidepressants prescribed in the U.S. In addition, in 2011, we had the results of the FLAME trial suggesting that early poststroke treatment with fluoxetine, a commonly prescribed SSRI, improves motor recovery and functional independence in stroke patients with motor deficit. Though these results were not replicated in the subsequent larger FOCUS trial, the use of SSRIs poststroke dramatically increased over the past decade. So what are the side effects of using SSRIs poststroke? It's a known fact that adult stroke survivors are more likely to experience bone fracture, and that there's some evidence that SSRIs may increase this risk. Dr. Negar Asdaghi:         So, in the current issue of the journal, Dr. Graeme Hankey and Joshua Jones, from Faculty of Health and Medical Sciences, University of Western Australia, in Perth, and colleagues aimed to answer this question with a systematic review and meta-analysis of randomized controlled trials that included an SSRI treatment for an adult patient with a previous hemorrhagic or ischemic stroke and included incident fractures, either as a primary or secondary study outcome, amongst other criteria. So they found four randomized controlled trials that fulfilled their research criteria. Three of them looked at the effects of fluoxetine, used at a dose of 20 mg per day for six months duration, on functional recovery and outcomes after stroke. And one trial, which has studied neuroregeneration in vascular protection by citalopram, either at a 10 mg or 20 mg daily dose also for six months duration, in patients with acute ischemic stroke. So three studies included with fluoxetine and one study included citalopram. Dr. Negar Asdaghi:         So, what they found was that although the risk of falls, seizures and recurrent stroke were not statistically increased with SSRI treatment, it was actually a significant increased risk of fractures with a risk ratio of 2.36 in patients treated with SSRI as compared to the placebo. Now, how the SSRIs will increase the risk of fractures is still unknown. There are multiple postulated mechanisms that are discussed in the paper, such as SSRIs potentially increasing spastic motor activity, causing orthostatic hypotension, dizziness, delayed reaction time or temporary imbalance or sleep disorders. But the most important mechanism to keep in mind is the possibility of SSRIs lowering bone mineral density. It's also important to note that the duration of exposure to SSRIs is an important predictor of factors. It's worth noting that the usual SSRI exposure in patients with the primary diagnosis of depression is a lot longer than the exposure time in these trials. Dr. Negar Asdaghi:         So, what are the top two takeaway points for stroke physicians? Number one: Fluoxetine and citalopram SSRIs, used for six months poststroke, double the risk of fracture as compared to placebo in this meta-analysis. Number two: While the mechanism of this association is still debated, fracture prevention should be an important discussion point when considering prescribing an SSRI to stroke patients. Dr. Negar Asdaghi:         We all know that carotid disease is a major cause of ischemic stroke. Now we have to keep in mind that the bulk of the literature in carotid disease are practically concentrated on the association between the degree of luminal stenosis and the risk of recurrent stroke. So, in practice, we constantly counsel and discuss risk of future ischemia in symptomatic and asymptomatic carotid disease based on the degree of stenosis that's less than 50%, or between 50% to 70%, or over 70%. Dr. Negar Asdaghi:         But what if we learn that some plaques can be active despite causing small or little stenosis? And conversely, some may be active despite being very large. There seems to be a growing literature that much of the recurrent strokes are occurring in destabilized plaques. And it turns out that there are actually biomarkers that could cause this destabilization, and we can actually measure them. Xanthine oxidase, or XO, is one of these biomarkers. XO is a key enzyme involved in degradation of purine into uric acid. Now I'm trying to simplify a complex subject here. Xanthine oxidase oxidizes the conversion of hypoxanthine into xanthine and xanthine into uric acid. Along the way, it also does create a whole bunch of reactive oxygen species such as superoxide and hydrogen peroxide, which can create tissue damage. Dr. Negar Asdaghi:         Now, how is XO and serum uric acid levels related to carotid disease? Well, it turns out that XO is enhanced in carotid arteries with evidence of atherosclerosis. Better yet, in animal models, inhibition of XO is associated with reduction in progression of atherosclerosis. So, in the current issue of the journal, Drs. Morsaleh Ganji and Valentina Nardi, from Departments of Cardiovascular Medicine and Anatomic Pathology of Mayo Clinic in Rochester, Minnesota, and colleagues set out to investigate whether carotid plaques from symptomatic patients had increased expression of xanthine oxidase than their asymptomatic counterparts. So, what they did was they looked at 88 patients undergoing carotid endarterectomy for symptomatic or asymptomatic carotid disease, part of the routine clinical practice, and then measured the XO expression by immunohistochemical staining in CA obtained specimens. Dr. Negar Asdaghi:         In addition, they collected a number of serum samples and other demographics and vascular risk factors from the participating patients. They found four major findings in their paper. Number one: XO expression was indeed higher in symptomatic carotid arteries. Number two: Symptomatic patients had a higher serum uric acid levels. Number three: Higher XO expression was inversely associated with the serum levels of HDL. Number four: The symptomatic plaques had higher amount of macrophages expressing XO. Dr. Negar Asdaghi:         Very interesting, but these findings were irrespective of the actual degree of luminal stenosis. In fact, the asymptomatic carotid plaques patients, as routine practice dictates, had a higher degree of luminal stenosis, but they had lower expression of XO and other associated findings. So what did we learn from this study? Well, there seems to be a strong association between certain biomarkers, in this case xanthine oxidase, and symptomatic state of carotid plaques, suggesting that perhaps in future we'll have other ways of measurements that may help us decide on carotid intervention rather than just the symptomatic state of the artery and the degree of stenosis. Dr. Negar Asdaghi:         It's been over 25 years since alteplase was approved as the thrombolytic agent of choice for treatment of patients with acute ischemic stroke. But in the past decade, tenecteplase, a genetically modified variant of alteplase with regulatory approval for treatment of ST-segment–elevation, myocardial infarction, has gained interest as an alternative reperfusion therapy for treatment of patients with acute ischemic stroke. Whether tenecteplase is ready to completely replace alteplase in clinical practice is certainly a burning question faced by the stroke community today. This was the subject of a lively debate at the most recent and entirely virtual 2021 International Stroke Conference, where a panel of experts reviewed the current evidence regarding the use of tenecteplase in acute ischemic stroke, examining data from animal models, preclinical studies to dose escalation studies and randomized trials, directly comparing tenecteplase with alteplase, as well as the collective clinical experience to date with this thrombolytic agent. Dr. Negar Asdaghi:         The proponents of change point out the many advantages of tenecteplase over alteplase, including its ease of use, increased fibrin specificity, longer half-time and its non-inferiority to alteplase in the head-to-head trials. On the other hand, the opponents caution stroke physicians, drawing attention to the inherent issues with the already completed clinical trials of tenecteplase, and argue that more data is needed before tenecteplase is considered as a thrombolytic agent of choice in routine clinical practice. Continuing on this debate in the September issue of the journal as part of the Controversies in Stroke series, Drs. Jeffrey Saver and May Nour provide opposing views to Drs. Dawn Kleindorfer and Mollie McDermott on the present evidence and current guidelines around tenecteplase use in acute ischemic stroke. Dr. Negar Asdaghi:         Acting as moderators, the senior authors of paper, Dr. Jukka Putaala, Head of Stroke Unit at Neurocenter, Helsinki University Hospital, and Dr. Markku Kaste, Emeritus Professor of Neurology at the University of Helsinki and past chairman of Neurocenter, Helsinki University Hospital, in Finland, provide us with the balancing remarks on the issue. I'm joined today by Professors Putaala and Kaste to give us an overview on the debate of tenecteplase versus alteplase. Is it time to make the switch? Good morning from sunny Florida and good afternoon to you both in Finland. Thank you for joining us on the podcast. I hope the weather is as beautiful in Helsinki today as it is here in Miami. Dr. Jukka Putaala:           Here it is not as warm as you have, but we have had a really beautiful summer, and at the moment, although it is also autumn, temperature is around 20 Celsius, so it's just great. Dr. Negar Asdaghi:         It's great to have you both. The paper outlines a generally recognized criteria to support the use of any new pharmacotherapy. Can you please start us off by reviewing the components of this criteria and tell us, please, how many checkmarks does TNK get on this checklist when considered as a reperfusion therapy in acute ischemic stroke? Dr. Jukka Putaala:           These eight criteria include a well-characterized mechanism of action; strong preclinical data; evidence of benefits and safety in a closely related clinical condition, which here is myocardial infarction; important practical advantages over existing agents; the clinical efficacy in how the patient has demonstrated in randomized trials; and endorsement by national practice guidelines. Also, support from regulatory authorities. And finally, clinical effectiveness, which has demonstrated in routine care. We think that tenecteplase for acute ischemic stroke meets actually all of these eight criteria. But we could also think that a smaller number of criteria will be enough to satisfy or meet, would be sufficient. Dr. Negar Asdaghi:         Perfect. So definitely many important steps, starting with the basics all the way to post-marketing clinical experience. Markku, now over to you. Can you remind us about the mechanism of action of tenecteplase? And what are some of the similarities and differences in terms of pharmacodynamic and pharmacokinetics with alteplase? Dr. Markku Kaste:           So alteplase catalyze plasminogen cleavage to plasmin and, in turn, degrades fibrin in thrombi, yielding clot lysis. TNK, compared to alteplase, is 14-fold greater fibrin activity and 80 times higher resistance to plasminogen activator inhibitor-1, which means it has a longer half-life, which is a major advantage. Patients need only one injection. In case you're compared to alteplase, when you had to have third dose injection and then one-hour infusion, which delay the care of patient, if the patient need thrombectomy. So it takes an hour for the infusion before patient can be transferred to thrombectomy, and time matters in brain infarction. So the faster you are, the better it is for patients. Dr. Negar Asdaghi:         Perfect. So more fibrin specificity, as you mentioned, and longer half-time for TNK. And in addition, TNK is not a new drug. In fact, there is over two decades' worth of experience with this in cardiology. Can you also tell us about this? And also some of the preclinical and animal studies that make TNK a potential candidate as a thrombolytic therapy in stroke? Dr. Markku Kaste:           In animal studies, both in vitro model of mural platelet deposits under arterial flow and a rabbit model using extracorporeal arterial-venous shunts, TNK was more potent, showing benefits up to three hours versus one hour when alteplase was used. So, it's a major benefit already in animal experiments and in the code team, of course, it will be transferred in clinical practice. So, in myocardial infarctions, in three randomized trials, including our 17,000 patients, TNK showed significant reduction for bleeding rates and similar intracerebral hemorrhage rates and 30-day mortality. Dr. Markku Kaste:           So, these facts support the use of TNK, also in ischemic stroke, the results from myocardial infarction, some steady encouraging. Although we have to keep in mind that myocardial infarction is very homogeneous disease, it's arterial occlusion, while ischemic stroke can be caused by the local occlusion just like myocardial infarction, but also from artery-to-artery thrombi or from a cardiac emboli. And these three [inaudible 00:17:43] mechanisms generate different kind of thrombi, so we need a better drug than alteplase, which really is effective, whatever is the etiology of the occlusion of brain artery. Dr. Negar Asdaghi:         Right. Thank you. Jukka, now over to you. Before we review the data from randomized trials of tenecteplase, can you please tell us about some of the practical advantages of tenecteplase over alteplase? We're comfortable with alteplase. Why should we make the switch? Dr. Jukka Putaala:           The key practical advantages arise from the fact that tenecteplase can be given as one single dose; it takes only one minute. And if you compare that to alteplase, you'll have to give the bolus first, and then following the bolus is 60 minutes infusion. And that also has many advantages in clinical practice, for example, if you have a patient with large vessel occlusion in a remote hospital, which is not thrombectomy-capable, you can give tenecteplase and then put the patient in the ambulance and transfer swiftly the patient to the thrombectomy center. While, when using alteplase, you have to start infusion, which you have to have the nursing staff that is capable of monitoring the infusion and taking care of any complications arising during the infusion and so forth. Dr. Jukka Putaala:           With tenecteplase, you can immediately transport the patient to a thrombectomy site after the bolus without any infusion-capable paramedics staff. Another practical advantage is that by using tenecteplase, you avoid the potential gap between the bolus and the infusion, which means that there is at least several minutes or longer gap in four out of five patients treated with alteplase. You can also think the other scenarios during this coronavirus era, and you have 15 patients with suspected or very fast coronavirus infection. By using bolus, you don't need to put nurses in the same room with the patients many times with the infusion if you use alteplase. Instead, you can use tenecteplase, it's only one single bolus, and you can go away and you don't have to be exposed to potential coronavirus infection. Dr. Negar Asdaghi:         So, many important advantages, as you mentioned. It seems very reasonable, then, to use tenecteplase in routine practice if it is indeed non-inferior to alteplase. Jukka, what dose of tenecteplase should be used for treatment of acute ischemic stroke patients? And we're definitely excited to hear about the head-to-head trials with tenecteplase versus alteplase. Dr. Jukka Putaala:           Well, the trial, the dose is 0.25 mg/kg or 0.4 mg/kg. It depends if you have LVO, if you review the evidence what we have now available, you have to use the lower dose in LVO patients. But you can use the higher dose in non-LVO patients. All of this arises from the evidence we have available right now. So, basically, five randomized trials have been completed, to date, comparing tenecteplase with alteplase in acute ischemic stroke. And shortly, if they pull out these five trials and compare primary outcome, which is modified Rankin Scale 0 to 1 versus prior, which means excellent outcome. Dr. Jukka Putaala:           So, when pulling out these five trials, 58% percent of patients rates excellent outcome versus 55% of alteplase, and this satisfied the criteria for non-inferiority. Regarding safety and secondary outcomes, major intracranial bleeding, mortality, this meta-analysis according to five trials shows similar results for tenecteplase and alteplase. You have to consider some details of this trial. I think Markku was going to quickly review some of the details of the science and doses used in these trials later on. Dr. Negar Asdaghi:         So, yes, this sounds great for tenecteplase, but so now over to you, Markku. As Jukka mentioned, do we hear a "not so fast for tenecteplase"? Is the current data enough to say goodbye to alteplase entirely and completely turn over to tenecteplase? What are some of the issues with the already completed trials? Dr. Markku Kaste:           It's not today, we cannot say goodbye to alteplase. As Jukka referred to those trials, there's no reason to go into these really deep details because the trials are quite small compared to ordinary clinical randomized trials studying stroke care. Like I don't want to give neuroprotection agents, for example. One larger trial was, let's say, reasonably well designed. But as to say that most of these trials are not really double-blind randomized clinical trials. And so the results which can be generated is not as reliable as double-blind trials because, of course, there are reasons, I mean, colleagues randomizing cases may think that, OK, a randomizing case and I'm not totally convinced about TNK. And I think this gentleman or this lady really needs effective thrombolytic agents, so I give alteplase, while if another patient with a mild symptom, same physician may think, OK, this stroke patient will recover no matter what, so let us randomize the patient. Dr. Markku Kaste:           So, it means these kind of unbalanced randomization provides data which is not really reliable. We had to have lots double-blinded randomized trials before it's time to say goodbye, if this double-blinded randomized trial verified that TNK beats alteplase. And, of course, we need also meta-analysis of those advanced trials, and these things can take time, although many guidelines, like AHA guidelines, European Stroke Organization guidelines, Chinese guidelines, Indian guidelines, they, in a way, how do you say, might recommend use of TNK, but I think we need more reliable scientific evidence before it's time to say goodbye to alteplase. Dr. Negar Asdaghi:         So, Jukka, Markku already alluded to this. I wanted you to review this for our listeners, the national practice guidelines and drug regulatory authority guidelines around the globe with regards to the issue of tenecteplase versus alteplase. Dr. Jukka Putaala:           Yeah, actually, already American, European, Chinese, Australian and Indian guidelines are recommending tenecteplase into the guidelines, which were recently published in 2019, between 2019 and 2021. What we can read from the guidelines is that tenecteplase can be considered over alteplase. But we have to remember that the strength of the recommendation will remain weak at present and quality of evidence is by the facts that we discussed of these five completely randomized trials and meta-analysis pulling out the data. Qualitative evidence remains slow, and, therefore, the wording in the guidelines is that it may be reasonable to choose or consider alteplase. Tenecteplase might be considered as an alternative to alteplase in certain conditions. Dr. Jukka Putaala:           The recommendations are a little bit mixed in the guidelines, but generally, in large vessel occlusions, the guidelines say that you could consider TNK over alteplase or even that you should consider TNK over alteplase in large vessel occlusion before proceeding to thrombectomy. However, in cases without large vessel occlusion, the statements are more mixed and they say tenecteplase might be considered or even that alteplase is preferred over tenecteplase until we have more evidence. Dr. Negar Asdaghi:         Thank you, Jukka. Markku, what should be our final takeaway message for the practicing stroke physicians at this point considering the use of tenecteplase in routine practice?   Dr. Markku Kaste:           Before your paper has been accepted and published in high-quality journal, it takes weeks, mostly it takes months, even a half a year. While in Stroke Conference, you get the most recent data, which is, let's say, generated last week or even the same day. So, when you want to really provide high-quality care of your patient, keep you updated. And then it's best for you and her, and it's better, of course, for your patient. International Stroke Conference and also European Stroke Conference, they are excellent places to get the most recent, yet unpublished, reliable information. Dr. Negar Asdaghi:         Professors Jukka Putaala and Markku Kaste, thank you for summarizing a large body of evidence for our listeners. We're definitely excited to learn how tenecteplase will ultimately stand against the old competitor and perhaps learn that both may be reasonable thrombolytic options, depending on the specifics of the clinical setting. Dr. Negar Asdaghi:         And this concludes our podcast for the September 2021 issue of Stroke. Please be sure to check the September table of contents for the full list of publications, including two special reports on consensus recommendations from the 11th STAIR Consortium, that is, Stroke Treatment Academic Industry Roundtable. Dr. Negar Asdaghi:         The first report is intended to enhance patient, clinician and policymaker comprehension at modified Rankin Scale findings in clinical trials and quality improvement initiatives. The second report from the STAIR Consortium is on top priorities for cerebroprotective studies, an important manuscript where the roundtable considered and presented a new paradigm for evaluation of putative therapies that may work together with recanalization treatments to improve outcome after ischemic stroke, with special attention to using the correct nomenclature, such as replacing the term "neuroprotection" with "cerebroprotection" when the intention of an investigation is to demonstrate that a new treatment benefits the entire brain, rather than neurons alone. Or replacing the term "time window" with "tissue window" or "target window" when selecting patients for recanalization therapies to enhance the notion that various elements of the neurovascular unit show vulnerability to ischemia evolving over different time scales in different brain regions. An important paradigm shift in ways we think of the brain under ischemic attack. With that, we invite you to continue to stay alert with Stroke Alert. Dr. Negar Asdaghi:         This program is copyright of the American Heart Association, 2021. The opinions expressed by speakers in this podcast are their own and not necessarily those of the editors or of the American Heart Association. For more, visit AHAjournals.org.

Test your pathology knowledge with our next Quiz Show! Join hosts Dr. Sara Jiang (@Sara_Jiang) and Dr. Nicole Riddle (@NRiddleMD).  Our guests, Dr. Sue Chang (@SueChangMD), Clinical Assistant Professor and Chief of Anatomic Pathology at City of Hope, LA, Dr. Gagandeep Kaur (@Gagandeepk5MD), Chief Resident (PGY4) at Danbury Hospital in CT, and Dr. Thomas Denize (@AnotherPathres), postdoctoral fellow at Brigham and Women's in Boston play our games and attempt to win an exclusive PathPod clear ruler!    Featured public domain music by The U.S. Army Blues

Hi Friends, This is Dr. Michael Williams,  and welcome to another episode of the diversify in path podcast.This podcast explores how  investing in diversity  can lead to  a high return of investment in pathology and laboratory medicine by learning from the knowledge and experiences of  diverse voices within in our field.  My next guest is Dr. Eddie Lee.Dr. Lee obtained his M.D. and Ph.D. degrees from the University of Pennsylvania in 2005 where he studied amyloid pathology in various experimental models under the mentorship of Virginia M.-Y. Lee, PhD.  After clinical training in Anatomic Pathology and Neuropathology at the Hospital of the University of Pennsylvania, he was appointed Assistant Professor in 2011 and promoted to Associate Professor with tenure in 2021 in the Department of Pathology and Laboratory Medicine at the University of Pennsylvania.   In addition to being an attending pathologist,  Dr.Lee has   served in may leadership and research roles  , has  served on multiple study sections for the NIH and the DoD and is on the editorial board for various Neuropathology publications.Twitter: @TNRLabWebsite:  Home | Translational Neuropathology Research Laboratory | Perelman School of Medicine at the University of Pennsylvania (upenn.edu)

Pathology administrators are tasked with the recruitment, retention, and management of laboratory staff. But how do you attract personnel for hard-to-fill positions? And how do you help young pathologists and laboratory professionals advance their careers and become the next generation of leaders?  On this episode of Inside the Lab, our hosts Dr. Lotte Mulder and Ms. Kelly Swails are joined by Ms. Kelley Suskie, MHSA, FACMPE, Administrator for the Department of Internal Medicine at the University of Arkansas for Medical Science, Mr. John Baci, MBA, C-PM, Executive Director of Anatomic Pathology at Boston Children's Hospital, and Mr. Martin Lawlor, Director of Finance and Administration for the Department of Pathology at Michigan Medicine, to discuss personnel management. Our panelists explain what administrators can do to prepare for the retirement cliff facing pathology, challenging laboratory professionals to mentor the next generation of leaders. They explore how personnel management differs in an academic versus clinical setting and offer strategies for networking in the pathology administration community. Listen in as our panelists share their most challenging personnel management experiences and get their advice on confronting bad behavior early on and holding people accountable for their actions as pathology administrators. Topics Covered  ·  Suggestions for recruiting and retaining personnel for hard-to-fill positions· Creating succession plans for the laboratory professionals ·  Preparing for the retirement cliff the pathology field is facing and developing the next generation of leaders· Why it's better to help top performers advance and move on rather than hold them back· How to reconcile making yourself invaluable in the lab with empowering your team· How personnel management differs in an academic vs. clinical setting· Strategies for connecting with others in the community of academic pathology administration· The importance of both internal and external networking in the personnel management space· Challenging personnel management experiences· Developing the courage to confront bad behavior early on and hold people accountable for their actions· Our panelists' advice around mentoring aspiring pathology administrators Connect with ASCP ASCPASCP on FacebookASCP on InstagramASCP on Twitter Connect with Ms. SuskieMs. Suskie on LinkedInMs. Suskie on Twitter Connect with Mr. Baci Mr. Baci at Boston Children's HospitalMr. Baci on LinkedIn Connect with Mr. Lawlor Mr. Lawlor at Michigan Medicine Connect with Dr. Mulder & Ms. Swails Dr. Mulder on TwitterMs. Swails on Twitter Resources Inside the Lab in the ASCP Store 

Always a visionary, Dr. Reuter was one of the earliest Anatomic Pathologists to embrace and advance the genomic and more recently the digital transformation of our field.In this episode of Meet The Expert series, Dr. Reuter shares his perspective and vision on the current and future impact of digital pathology See acast.com/privacy for privacy and opt-out information.

This episode is also available as a blog post: https://anatomicpathology.info/atlas-of-surgical-pathology-grossing-atlas-of-anatomic-pathology/ BUY BOOK FROM AMAZON - https://amzn.to/3ehxIxd

With so many use cases and applications in digital pathology, how do we connect the dots and make it all work? Dr. Anil Parwani is Professor of Pathology at The Ohio State University, Vice chair of Pathology and Head of Anatomic Pathology. He is the newly elected president of the Digital Pathology Association (DPA). We will talk about some of the ways to increase adoption and possible use cases for digital pathology. We will examine how algorithms and AI tools might help and what will be the role of pathologists if these algorithms work as promised. We will also look at some of the barriers to adoption including interoperability and storage.

SHOW NOTES: This week next level entrepreneur and I took the conversation to another level as we chatted about empowering our Latina Women Physicians Highlights from the conversation: Dr. Ursula Lang ● MD, PhD. Board Certified in both Anatomic Pathology and Dermatopathology ● Dedicated to helping Latina physicians and scientists through Latina Docs Podcast (with Dr. Vanessa Calderon) ● Immersed in coaching for the last four years, with over 1,000 hours of training and experience ● Loving wife, mother of two beautiful children, and fierce friend The importance of representation and empowerment ● Nobody else has the same combination of experiences, positions, connections. This uniqueness can be turned into a contribution and example for those that have similarities in one or more aspects with us, but can’t find them in mainstream media. ● Representation can give us perspective. Different parties voicing what they need and how they live their lives provides strength and value to the group they represent. ● It’s important to have people in your life you can go to or look up to, that can remind you who you are why you are doing what you're doing. ● Representation is part of a bigger machine. There are people in the front lines (that show up in manifestations, attacking the root of the problem, being extremely vocal), and behind them are those who empower them, and lift them up when they are burning down. ● Creativity is one of the roots of empowerment. Without it, so many tools (such as podcasts, coaching programs, videos, guides, etc) wouldn’t be available. These tools expand our minds and provide us with an impulse to look for better solutions. ● Someone decided that one color of one skin or one race was superior to others, and this kept going for so many years. It keeps going. Latino people and black people can have internalized that without realizing. This can be stopped by honoring our cultures, which can only be noticed and displayed through empowerment and representation. Without clearly visualizing it, there’s no way to combat the idea of white supremacy. ● This also works in other aspects, such as gender discrimination. Catch up with Dr. Lang by visiting her at www.lantinadocs.com Follow her on Social Media at: Facebook Page Facebook.com/groups/latinadocs Website Address Latinadocs.com Podcast Name Latina Docs See you on the next one! Hosted by: Dr. Maiysha Clairborne Looking for a Coach or Mastermind to Join? Ready to Take Your Career, Business, and Life to the Next Level? If you want to Learn more about Dr. Maiysha's coaching, courses, and masterminds. Visit www.DrMaiysha.com. Choose from of our Free Mini Online Masterclasses on Mindset Mastery, Manifestation, and Next Level Entrepreneurship Right on the Home page to start your journey now.

To get the best outcome for patients, communication between anatomic and clinical pathologists is critical. And although the field is small, specialists in infectious disease pathology are especially equipped to facilitate collaboration among AP and CP lab professionals. On this episode of Inside the Lab, our hosts Dr. Dan Milner and Ms. Kelly Swails are joined by Dr. Clare McCormick-Baw, MD, PhD, AP/CP-Trained Pathologist and Assistant Professor of Pathology at the University of Texas Southwestern Medical Center, Dr. Andrew Clark, PhD, D(ABMM), Associate Director of Microbiology at Clements University Hospital at the University of Texas Southwestern Medical Center, Dr. Jonathon Wilcox, MD, Third-Year AP/CP Resident at the University of Vermont Medical Center, and Ms. Karen Jaworski, MT(ASCP), Microbiology Supervisor at Parkland Health and Hospital System in Dallas, Texas, to discuss infectious disease as a bridge between anatomic pathology and clinical pathology. Our panelists explore the value of interfacing among infectious disease, clinical pathology and anatomic pathology professionals to improve patient care and what barriers exist in collaborations between anatomic pathologists and clinical microbiologists. Listen in for Dr. McCormick-Baw, Dr. Clark, Dr. Wilcox and Ms. Jaworski’s insight on how COVID has affected their working relationships and learn more about the unique, specialized field of infectious disease pathology. Topics Covered · What makes infectious disease pathology unique in terms of the division between anatomic pathology and clinical pathology· Why it’s crucial for AP and CP colleagues to communicate around infectious disease cases· The role the bench tech plays in IDP, AP and CP in terms of biosafety and patient care· How COVID has affected the panelist’s working relationships and how previously established relationships among departments improved their response to the pandemic· How AP-CP communication and infectious disease could be incorporated into diagnostic or multidisciplinary management teams· How advanced diagnostics and personalized medicine are likely to influence the future of AP, CP and IDP Connect with ASCP ASCPASCP on FacebookASCP on InstagramASCP on Twitter Connect with Dr. McCormick-Baw Dr. McCormick-Baw at UT Southwestern Connect with Dr. Clark Dr. Clark at UT Southwestern Connect with Dr. Wilcox The University of Vermont Medical Center Connect with Ms. Jaworski Ms. Jaworski on LinkedIn Connect with Ms. Swails & Dr. Milner Ms. Swails on TwitterDr. Milner on Twitter Resources Inside the Lab in the ASCP Store

Dr. Vanessa Smith is a practicing neuropathologist. She received her MD from the Mayo Clinic. Following completion of her internship at the Mayo Clinic, she returned to her hometown of Lexington and completed an Anatomic Pathology residency, followed by a Neuropathology fellowship at the University of Kentucky. Academically, she has presented her research at several national and international meetings and has been published in multiple peer-reviewed journals. She also directed and taught several didactic curricula for pathology, neurosurgery and neurology residents, receiving a departmental teaching award for her efforts in resident education.   Take the quiz here

Dr. Ross Reichard joins ScopeMD to discuss the role RFID technology in healthcare. Dr. Reichard outlines the different types of RFID technology and shares his experience with Mayo's radio-frequency identification specimen-tracking system. This tracking system was highlighted in the article entitled, "Radio-Frequency Identification Specimen Tracking to Improve Quality in Anatomic Pathology," which was published in the Archives of Pathology and Laboratory Medicine in February 2020. Dr. Reichard is a pathologist at the Mayo Clinic in Rochester, MN where he is the Vice Chair of Quality for the Department of Laboratory Medicine and Pathology. Dr. Reichard is involved in multiple national organizations and currently serves as President of the American Association of Neuropathologists (AANP). He is passionate about working with teams to evaluate and improve systems to improve patient care.Journal Article Andrew P. Norgan, Kurt E. Simon, Barbara A. Feehan, Lynn L. Saari, Joseph M. Doppler, G. Scott Welder, John A. Sedarski, Christopher T. Yoch, Nneka I. Comfere, John A. Martin, Brian J. Bartholmai, R. Ross Reichard; Radio-Frequency Identification Specimen Tracking to Improve Quality in Anatomic Pathology. Arch Pathol Lab Med 1 February 2020; 144 (2): 189–195. doi: https://doi.org/10.5858/arpa.2019-0011-OA

Inside-Out Leadership: Human Leadership and Mental Health with Dr. Alison Van Dyke Dr. Alison Van Dyke joined the Data Quality, Analysis, and Interpretation Branch of the Surveillance Research Program (SRP) as Director of the SEER-linked Virtual Tissue Repository (VTR) Pilot Studies. For the VTR Pilot Studies, SRP works with SEER registries to obtain custom annotations of detailed treatment data for pancreas and female breast cancer cases which may have biospecimens available. The goal is to match unusual survival cases with more typical survival controls. Dr. Van Dyke also directs the Residual Tissue Repositories (RTRs). Operated by the SEER registries in Hawaii, Iowa, and Los Angeles, the RTRs collect tissue being discarded by hospital laboratories once the minimum requirement for retaining diagnostic tissue blocks, as set forth by the College of American Pathologists (CAP), has been met.Prior to joining SRP, Dr. Van Dyke earned her MD/PhD from Wayne State University School of Medicine in 2011 with graduate training in cancer biology. Under the mentorship of Dr. Ann Schwartz, her doctoral research focused on the role of inflammation in non-small cell lung cancer among women and included SEER data. She completed postgraduate medical residency training in anatomic pathology at Yale-New Haven Hospital and surgical subspecialty training in thoracic pathology at the University of Pittsburgh Medical Center. In addition to being board certified in Anatomic Pathology by the American Board of Pathology, she is a Fellow of the CAP and serves as the SEER Liaison to the CAP Cancer Committee, which determines what and how tumor information will be reported in pathology reports.Dr. Van Dyke completed a postdoctoral fellowship in the Infections and Immunoepidemiology Branch of the Division of Cancer Epidemiology & Genetics (DCEG). Working with Drs. Jill Koshiol and Eric Engels in DCEG, Dr. Van Dyke's postdoctoral research focused on the incorporation of surgical pathology in epidemiologic research. She utilized data from the NCI Cancer Cohort Consortium to investigate the epidemiology of biliary tract cancers. She was also the first researcher to use the digital slide collection from the National Lung Screening Trial to investigate the relationships between lung scarring characteristics and lung cancer development. In addition, she established pathology tissue collection and evaluation methods for Dr. Koshiol’s Chile Biliary Longitudinal Study (Chile BiLS). She is completing a NAACCR project examining biliary tract cancer incidence trends in the United States.In this episode we discuss her path to being a MD/PhD, some of the projects she is working on currently at the NCI, the lessons she learned from living with Bipolar Disorder, and her experience as a woman in STEM. Questions we posed include: What it means to you to be a physician-scientist and why you chose this path? How does balancing these two professional identities affect your leadership philosophy? What things outside of medical school, research, and residency have you done that most impacted your leadership development? What are some Challenges/barriers that you faced? Why do you still think there is still such a stigma surrounding mental health? What needs to be emphasized during the training of young medical and scientific leaders in order to improve the culture? Do you have any personal stories where you felt that you were discriminated against by your peers for your gender?What message do you want to send to our listeners that may feel discriminated against based on their gender, race, etc? What are your favorite books? What advice do you have for medical trainees?

Dr. Kinloch is the division head for Anatomic Pathology for the Saskatchewan Health Authority in Saskatoon and is a subspecialty pathologist and clinical assistant professor at the University of Saskatchewan in the Department of Pathology and Laboratory Medicine. She completed medical school in Dublin, Ireland, residency in General Pathology at the University of Saskatchewan, and fellowship in Gynecologic Pathology at the University of British Columbia. Dr. Kinloch's research is primarily on the molecular classification of endometrial carcinoma, and quality improvement and standardization work within anatomic pathology, including tissue preservation in lung biomarker assessment in patients with advanced lung adenocarcinoma. Locally, Dr. Kinloch sits as the co-chair for anatomic pathology in the province, the vice president for the Saskatoon Regional Medical Association, and volunteer chair for the Women Leading Philanthropy campaign for the Royal University Hospital Foundation. Her work nationally is through her role on the executive of the Special Interest Group for Gynecologic Pathology and as a board member for the Canadian Association of Pathologists. Internationally, Dr. Kinloch is a member of the education committee for the International Association of Pathology. Show notes available at northernexposurepodcast.ca

Autopsies allow the dead to teach the living, and the information gathered by forensic pathologists is crucial in helping us understand what COVID-19 does to the body and improve patient care moving forward. So, what challenges have forensic pathologists and patient advocates faced through the pandemic? On this episode of Inside the Lab, moderators Dr. Lotte Mulder and Ms. Kelly Swails are joined by Ms. Lisbeth Harcourt, LMSW, Program Manager of Decedent Affairs at Michigan Medicine, Dr. Brandi McCleskey, MD, Assistant Professor in the Division of Forensics at the University of Alabama at Birmingham’s Department of Pathology, Dr. Paul Benson, MD, Associate Professor of Anatomic Pathology and Autopsy Section Head at the University of Alabama at Birmingham, and Dr. Allecia M. Wilson, MD, Director of Autopsy and Forensic Services at the University of Michigan and Chief Medical Examiner of Washtenaw and Livingston Counties, to explore how the coronavirus pandemic has impacted the work of forensic pathologists and medical social workers. The panelists explain how COVID has affected end-of-life care and bereavement services, sharing what their teams are doing to support the families of decedents and how the virus highlights the importance of forensic pathologists as an integral part of the healthcare team. Listen in to understand what precautions our panelists have taken to keep their staff members safe in this challenging time and learn how forensic pathologists are using their autopsy findings to serve the living. Key Takeaways · How the coronavirus has affected forensic pathology resources and caseloads· How COVID has impacted end-of-life care and bereavement services· How the coronavirus has changed processes in forensic pathology offices for the better· The challenges of transitioning to a COVID-capable autopsy service and the precautions to keep staff members safe· How the pandemic has blurred the lines between work and home life for forensic pathologists and medical social workers· What has been learned about COVID from autopsy findings and how those observations can be used to help the living· What the future of forensic pathology looks like and opportunities for autopsy research collaborations Connect with ASCP ASCPASCP on FacebookASCP on InstagramASCP on Twitter Connect with Ms. Harcourt Ms. Harcourt at Michigan MedicineMs. Harcourt on LinkedIn Connect with Dr. McCleskey Dr. McCleskey at UABDr. McCleskey on Twitter Connect with Dr. Benson Dr. Benson at UAB Connect with Dr. Wilson Dr. Wilson at the University of MichiganDr. Wilson on LinkedIn Connect with Dr. Mulder & Ms. Swails Dr. Mulder on TwitterMs. Swails on Twitter

Listen to our conversation with Andy Beck, founder and CEO of PathAI, a company that develops artificial intelligence technology for pathology. Andy earned his MD from Brown Medical School and completed residency and fellowship training in Anatomic Pathology and Molecular Genetic Pathology from Stanford University. He completed a PhD in Biomedical Informatics from Stanford University, where he developed one of the first machine-learning based systems for cancer pathology. He's been certified by the American Board of Pathology in Anatomic Pathology and Molecular Genetic Pathology. Prior to co-founding PathAI, he was on the faculty of Harvard Medical School in the Department of Pathology at Beth Israel Deaconess Medical Center. He has published over 110 papers in the fields of cancer biology, cancer pathology, and biomedical informatics.

In this episode of Lab Medicine Rounds, Rondell Graham, M.B.B.S., an Associate Professor of Laboratory Medicine and Pathology in the Divisions of Anatomic Pathology and Laboratory Genetics and Genomics at Mayo Clinic, discusses his recommendations for a successful start as an academic pathologist.

Dr. Meredith Reynolds, Augustana Class of 2012, talks about her residency at the University of Chicago Medical Center and how even an introvert can get lonely during these times of isolation. Music performed by the Northlanders Jazz Band and guest artist Jeff Coffin, under the direction of Dr. Brian Hanegan.

In this episode, we celebrate Father’s Day with stories from pathologists and their Fathers. Dr. Kalisha Hill (@kalishahillmd), Chief Medical Officer at AMITA Health St. Mary's Hospital in Illinois, shares a conversation with her father Dr. Kim Williams, Chair of Cardiology at Rush University in Chicago. Dr. Celestine Trinidad (@celestrinmd), a pathologist in Metro Manila, Philippines shares how her father inspired her to go into medicine, and how the path veered from surgery to pathology. Dr. Michael Arnold (@MArnold_PedPath), Medical Director of Anatomic Pathology at Children’s Hospital of Colorado talks about his experiences as a father with his daughter Madelyn. Dr. Leilani Valdes(@LeilaniCLV), medical director for Regional Pathology Associates in Victoria, TX, shares her love of her father and the life lessons he imparted. In between Our Father’s Day tribute, we will have trainees share how they became interested in pathology. We hear from Dr. Anas Saad (@AnasSaad94), a Research Fellow at the Cleveland Clinic Foundation, Cleveland Ohio, and Dr. Greta Evaristo (@gtevaristomd), 3rd year AP resident from McGill University, Montreal. Featured public domain music: Loyalty Freak Music, Dirty shoes blues.

The chromogen siblings talk with Dr. Kevin Zeng, Senior Molecular Scientist at the United States Army Medical Research Institute of Infectious Diseases (USAMRIID), about his recent publication in JCI Insight describing IHC and in situ hybridization methods for detecting SARS-CoV-2. Featured public domain music: Alpha Hydrae, Won't see it comin'.

In this week’s episode, we welcome Dr. Joanna Walsh onto the show to talk about her unconventional yet enthralling route to where she is today as an Anatomic Pathologist at LHSC! Dr. Walsh shares with us the intricacies of her profession, describes the different types of Pathology, walks us through the steps involved in processing and turning over a specimen, clarifies misconceptions about the specialty, and discusses the type of personality that excels in a career in Pathology. We also put Dr. Walsh in the ‘hot seat’ for a new segment of the show we are trying out to try and further personalize our guests! Thanks for tuning to Multipotent MD for another week with your co-hosts Ziad and Christopher.

Interview with Joaquin Garcia, M.D. and Justin Kreuter, M.D. This episode will discuss the perplexing work of salivary glands. Benign and malignant salivary gland tumors reveal overlapping clinical and pathologic features, imposing dramatic diagnostic and therapeutic challenges.

Dr. David Berman is Head of Research and Development at Immunocore, a leading T cell receptor biotechnology company. David and his team are working on new therapies that can train the immune system to recognize and kill cancer. This approach to treating cancer is called immunotherapy. Immunocore is taking a novel approach to immunotherapy by leveraging the mechanisms used by T cell receptors to identify indicators of cancer within cancer cells. Much of David’s time outside of work is spent driving his daughters to their soccer and lacrosse games and watching them play. He also enjoys cycling with his family and thought-provoking solo cycling outings. He received his bachelor’s degree in biology from the Massachusetts Institute of Technology. Afterwards, David was awarded his PhD under the mentorship of Dr. Alfred Gilman (Nobel Prize 1994) and his MD from the University of Texas Southwestern Medical Center at Dallas. He completed his Residency in Anatomic Pathology at the National Cancer Institute and a Fellowship in Pathology at The Johns Hopkins University School of Medicine. David then began his 10-year tenure at Bristol-Myers Squibb, where he held various senior development roles in immuno-oncology. He then spent three years in immuno-oncology leadership positions at MedImmune and AstraZeneca. In our interview, David shares more about his life and science.

This week our guest is Dr. Jeff Johnston who serves as the Chief Medical Examiner for the Maricopa County Office of the Medical Examiner; a position he has held since 2013. He oversees the Office which provides all statutory forensic medical death investigations for the 4th-most populous and fastest growing county in the the United States. Dr. Johnston holds a Bachelor’s Degree in Biology from the University of Virginia and a Medical Doctorate from the University of Louisville School of Medicine. He trained in Anatomic Pathology at the University of Tennessee Medical Center at Knoxville, home of the University of Tennessee’s Anthropology Research Facility. He has subspecialty training in Forensic Pathology from the Miami-Dade County Medical Examiner’s Office and is Board Certified by the American Board of Pathology in both Anatomic Pathology and Forensic Pathology. He has performing Medical Examiner work for the public since 2002.

Maximizing patient safety and reducing diagnostic errors is rooted in a quality management approach. The manual Quality Management in Anatomic Pathology (https://capatholo.gy/2UNJ9lk) provides pathologists and laboratory directors with the tools necessary to implement a comprehensive quality program, with an emphasis on regulatory compliance and cross-references to the CAP Laboratory Accreditation Program checklists and CLIA. In this CAPcast, one of the book’s co-authors, Dr. Gene Siegal, discusses the challenges related to quality, the common causes of error, and the key elements of a comprehensive quality program.

In this episode, Dr. Radha Krishnan describes three key challenges in immuno-oncology development related to anatomic pathology. Some of the key challenges organizations that support clinical trials I-O drug development see, particularly with the context of companion diagnostics, involves ensuring the sample availability is adequate and appropriate for the different clinical trials, that the assay outcome is useful and the results are relevant for the clinical trials. It is discussed how having adequacy of tissue samples is one of the most critical components. It's also important that the sites that are sending samples have the ability to process samples in a timely manner, establishing that the fixation and other pre-analytical conditions that influence the outcome of the results are well evaluated. Dr. Krishnan provides a vision that will make the whole process easier for patients and doctors alike.  

Episode Title: ACL Laboratories-Wisconsin Featuring: Janet McKnight Janet's Advice for Becoming a Histologist: “I would recommend becoming a lab assistant, we have seen so much success learning that foundation as a lab assistant at the ground level, so they understand what the work would be, so they're not investing that time in a school before they really know what they want to be.” Episode Description: In this episode, Janet McKnight, the Director of Anatomic Pathology for Wisconsin ACL Laboratories, discusses how ACL's training practices have helped them keep their lab staffed, while so many suffer shortages. ACL has been lucky enough to have their own histology school, which has helped them grow their lab assistants into full time histotechs, through the school's one-year program.

Mayo Medical Laboratories President William Morice, M.D., Ph.D., sits down with the new chair of the Mayo Clinic Division of Anatomic Pathology, Amy Clayton, M.D. The two discuss the role, leadership, and a shared history.

ISO 15189 is an international quality standard for medical laboratories. One of the best practices addressed in this standard is risk management. In this CAPcast from the College of American Pathologists, Dr. Frank Schneider, chair of CAP’s 15189 Committee, discusses ISO 15189 and risk management. Dr. Schneider, a pathologist at Emory University Hospital in Atlanta, Georgia, is also the co-author of a chapter on this topic in the new book, Quality Management in Anatomic Pathology, out now from CAP Press: http://capatholo.gy/2tnSsi1. The CAP 15189 program has issued a Risk Management Guideline that provides additional detail about the ISO 15189 requirements for risk management: http://capatholo.gy/2vjbeo4.

Workshop Title: Proficiency Testing in the Anatomic Pathology Laboratory Presenters: Jeremy Johnston Interviewer: Kathy Dwyer Best Interview One-Liner: "You really don't know what you don't know..." Visit www.histoconvention.org for complete information!

Today I am extremely pleased to interview Dr. William James Garner to discuss How to Reduce the Risk of Pharmaceutical and Biotech Investing. He performed his residency training in Anatomic Pathology at Columbia-Presbyterian and is a licensed Physician in the State of New York. He is a US Physician and Entrepreneur. Dr. Garner earned a Master of Public Health from Harvard University and received his M.D. degree from New York Medical College. He was a resident in pathology at Columbia-Presbyterian in NYC. He was recruited by a Wall Street boutique. Newly minted Dr. Garner began searching out patents that could be brought to market through a shell. He has succeeded with three thus far. His focus today is on advancing technologies and companies at significant value inflection points. Bill monetizes firm assets via licensing, M&A or IPO transactions. He is currently Chairman of both an ASX-listed and a public Canadian company. The student alumni association of the University of Puerto School of Business is proud to present Dr. Bill Garner. Question 1: Welcome to the show today Bill. In your own words, how did you get started at this? Dr. William (Bill) Garner's book on Amazon Kindle is "Garnering Capital: Make the Right Decisions. Penetrate the Market. Achieve Profitability."

ISO 15189, an international quality standard for medical laboratories, has the potential to improve the quality of anatomic pathology services, explains Dr. Frank Schneider, a pathologist with Kaiser Permanente in Northern California who chairs the CAP’s ISO 15189 Committee. Dr. Schneider is the co-author of a chapter on this topic in the new book, Quality Management in Anatomic Pathology, out now from CAP Press. For more information on ISO 15189, read this CAP FAQ document: http://capatholo.gy/2qx96Gi.

On today's DiabetesPowerShow, Charlie Cherry, Chris Moore, Theresa Moore, and Chris Daniel talk about Pets with Diabetes. This episode is dedicated to Chris Moore's Daughter, Angelica, whose sweet puppy passed away last weekend.  We welcome 3 special guests in studio: Nicholas Vitale DVM Nicholas grew up in Metro Detroit, and knew from a young age that he wanted to, some day, become a veterinarian. He attended undergraduate studies at Michigan State University, and holds a degree in Zoo and Aquarium Science. He then attended veterinary school, also at Michigan State, and graduated in 2011. Nicholas originally went into veterinary medicine because he wanted to be a zoo veterinarian. However, as things and interests changed, he decided that he wanted to become a pathologist. Post veterinary school, he attended and began a Residency in Anatomic Pathology at Cornell University. After approximately one year, Nicholas decided that pathology was not where he wanted to be in the veterinary medicine world. He moved back home, where he spent another year in Detroit, practicing small animal medicine. Nicholas moved to Las Vegas three years ago, and has been practicing at Desert Inn Animal Hospital ever since. Currently, he is preparing for, and studying to sit for his board accreditation, through the American Board of Veterinary Practitioners. When not working, Nicholas spends a lot of his free time volunteering, and being with friends. He is highly involved with The Desert Tortoise Foundation, as well as The Department of Fisheries and Wildlife, and with Desert Tortoise Research and Health Monitoring. He is also involved with legal cases with Clark County Animal Control. He has a "zoo" at home, including a French Bulldog named Odin, two parrots, Finn and Jager, two ferrets, Reason and Single, as well as a tiny desert tortoise, nameless, and a bearded dragon, who is also nameless. Norma Silverman Norma is a cat lover, who rescued and adopted ‘Nutmeg’. She joins us in studio, to share her experiences with the diagnosis, treatment, and ultimately the loss of her special friend, due to complications from Diabetes. Jim Holtz RN Jim is Theresa’s boss in the Hospital Emergency Room. He is a Registered Nurse, and Manager of Critical Care. He has many years of experience as a Medical Professional. Jim tells us how frustrating it was, as a professional who cares for people in the hospital, not to recognize the signs and symptoms of Diabetes in ‘Morgan’ and ‘Gabby’, his four-legged friends at home. What are the odds…not just one dog with Diabetes…but two?    

Dr. Alison Bested is a Haematological Pathologist. Her training covered a wide variety of areas including Immunology, Immunohaematology, Genetics, Anatomic Pathology, Internal Medicine, Clinical and Laboratory Haematology. Dr. Bested has been privileged to treat patients with Chronic Fatigue Syndrome, Fibromyalgia and Multiple Chemical Sensitivities for the past 20 years. An internationally acclaimed expert on complex chronic diseases, she  joined BC Women’s Hospital + Health Centre as the inaugural medical director of the Complex Chronic Diseases Program in October of last year.  This episode of Pain Waves Radio is generously sponsored by the personal injury lawyers at the law firm of Watson Goepel.

Click here for audio of lecture.

Dr. Mitch Mally Chiropractic Physician EDUCATION: 1974 – 1978: Pre-Medical Program Wayne State University, Detroit Michigan. Assisted Dr. Lyda Mattman, PhD, in research in Biochemistry, Immunology, and observational rounds in Electron Microscopy, Histology, Surgical and Anatomic Pathology and Cytology. 1978 -1981.: Palmer College of Chiropractic – Served as Honorary Intern in senior year, assisting student... The post ChiroHustle Podcast 123 – Mitch Mally, DC appeared first on Chiro Hustle.